MedKoo Cat#: 319615 | Name: Moexipril hydrochloride
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Moexipril is a potent orally active nonsulfhydryl angiotensin converting enzyme inhibitor (ACE inhibitor) which is used for the treatment of hypertension and congestive heart failure. Moexipril can be administered alone or with other antihypertensives or diuretics. It works by inhibiting the conversion of angiotensin I to angiotensin II.

Chemical Structure

Moexipril hydrochloride
Moexipril hydrochloride
CAS#82586-52-5 (HCl salt); 103775-10-6 (free base).

Theoretical Analysis

MedKoo Cat#: 319615

Name: Moexipril hydrochloride

CAS#: 82586-52-5 (HCl salt); 103775-10-6 (free base).

Chemical Formula: C27H35ClN2O7

Exact Mass:

Molecular Weight: 535.03

Elemental Analysis: C, 60.61; H, 6.59; Cl, 6.63; N, 5.24; O, 20.93

Price and Availability

Size Price Availability Quantity
10mg USD 275.00
50mg USD 400.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
RS 10085; RS-10085; RS10085; SPM-925; SPM 925; SPM925; CI-925; CI 925; CI925; Moexipril. trade name Univasc.
IUPAC/Chemical Name
2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride
InChi Key
JXRAXHBVZQZSIC-QGCARJLFSA-N
InChi Code
InChI=1S/C27H34N2O7.ClH/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32;/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32);1H/t17-,21-,22?;/m0./s1
SMILES Code
O=C(C1N(C([C@@H](N[C@H](C(OCC)=O)CCC2=CC=CC=C2)C)=O)CC3=C(C=C(OC)C(OC)=C3)C1)O.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
Moexipril hydrochloride (RS-10085) is an orally active inhibitor of angiotensin-converting enzyme (ACE).
In vitro activity:
With this objective, this study utilised a high-throughput computational approach that identified moexipril, a well tolerated and safe angiotensin-converting enzyme (ACE) inhibitor, as a PDE4 inhibitor. Experimentally this study showed that moexipril and two structurally related analogues acted in the micro molar range to inhibit PDE4 activity. Employing a FRET-based biosensor constructed from the nucleotide binding domain of the type 1 exchange protein activated by cAMP, EPAC1, this study demonstrated that moexipril markedly potentiated the ability of forskolin to increase intracellular cAMP levels. Finally, this study demonstrated that the PDE4 inhibitory effect of moexipril is functionally able to induce phosphorylation of the small heat shock protein, Hsp20, by cAMP dependent protein kinase A. Reference: Biochem Pharmacol. 2013 May 1;85(9):1297-305. https://pubmed.ncbi.nlm.nih.gov/23473803/
In vivo activity:
The purpose of the study was to establish the effect of moexipril on catalase activity and to compare it with the effect of both saline controls and that of the known PPAR agonist clofibrate (positive control). High-dose subchronic exposure to the ACE-inhibitor moexipril induces catalase activity in the rat liver to an extent comparable to fibrates. Reference: Mol Cell Biochem. 2005 Dec;280(1-2):159-63. https://pubmed.ncbi.nlm.nih.gov/16311918/
Solvent mg/mL mM
Solubility
DMF 10.0 18.69
DMSO 100.0 186.90
Ethanol 25.0 46.73
PBS (pH 7.2) 0.3 0.62
Water 100.0 186.90
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 535.03 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Cameron RT, Coleman RG, Day JP, Yalla KC, Houslay MD, Adams DR, Shoichet BK, Baillie GS. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). Biochem Pharmacol. 2013 May 1;85(9):1297-305. doi: 10.1016/j.bcp.2013.02.026. Epub 2013 Mar 5. PMID: 23473803; PMCID: PMC3625111. 2. Ravati A, Junker V, Kouklei M, Ahlemeyer B, Culmsee C, Krieglstein J. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol. 1999 May 28;373(1):21-33. doi: 10.1016/s0014-2999(99)00211-3. PMID: 10408248. 3. Adeghate E, Hasan MY, Ponery AS, Nurulain SM, Petroianu GA. Subchronic exposure to high-dose ACE-inhibitor moexipril induces catalase activity in rat liver. Mol Cell Biochem. 2005 Dec;280(1-2):159-63. doi: 10.1007/s11010-005-8843-6. PMID: 16311918. 4. Ma YF, Stimpel M, Liang H, Pun S, Jee WS. Impact of antihypertensive therapy on the skeleton: effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats. J Endocrinol. 1997 Sep;154(3):467-74. doi: 10.1677/joe.0.1540467. PMID: 9379124.
In vitro protocol:
1. Cameron RT, Coleman RG, Day JP, Yalla KC, Houslay MD, Adams DR, Shoichet BK, Baillie GS. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). Biochem Pharmacol. 2013 May 1;85(9):1297-305. doi: 10.1016/j.bcp.2013.02.026. Epub 2013 Mar 5. PMID: 23473803; PMCID: PMC3625111. 2. Ravati A, Junker V, Kouklei M, Ahlemeyer B, Culmsee C, Krieglstein J. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol. 1999 May 28;373(1):21-33. doi: 10.1016/s0014-2999(99)00211-3. PMID: 10408248.
In vivo protocol:
1. Adeghate E, Hasan MY, Ponery AS, Nurulain SM, Petroianu GA. Subchronic exposure to high-dose ACE-inhibitor moexipril induces catalase activity in rat liver. Mol Cell Biochem. 2005 Dec;280(1-2):159-63. doi: 10.1007/s11010-005-8843-6. PMID: 16311918. 2. Ma YF, Stimpel M, Liang H, Pun S, Jee WS. Impact of antihypertensive therapy on the skeleton: effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats. J Endocrinol. 1997 Sep;154(3):467-74. doi: 10.1677/joe.0.1540467. PMID: 9379124.
1: Chrysant GS, Nguyen PK. Moexipril and left ventricular hypertrophy. Vasc Health Risk Manag. 2007;3(1):23-30. Review. PubMed PMID: 17583172; PubMed Central PMCID: PMC1994034. 2: Ostroumova OD, Paukov SV, Frolova LI. [Angiotensin converting enzyme inhibitor moexipril in the treatment of arterial hypertension. Possibilities of moexipril in the treatment of postmenopausal women]. Kardiologiia. 2006;46(11):92-8. Review. Russian. PubMed PMID: 17159885. 3: [Moexipril and cardiovascular diseases in women: is there a reason for optimism?]. Kardiologiia. 2006;46(7):81-4. Review. Russian. PubMed PMID: 16883271. 4: Chrysant SG, Chrysant GS. Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. Review. PubMed PMID: 15286086. 5: Chrysant SG, Chrysant GS. Pharmacological profile and clinical use of moexipril. Expert Rev Cardiovasc Ther. 2003 Sep;1(3):345-52. Review. PubMed PMID: 15030263. 6: Pines A, Fisman EZ. ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control. Am J Cardiovasc Drugs. 2003;3(5):351-60. Review. PubMed PMID: 14728069. 7: Brogden RN, Wiseman LR. Moexipril. A review of its use in the management of essential hypertension. Drugs. 1998 Jun;55(6):845-60. Review. PubMed PMID: 9617599.